ES2156190T3 - Procedimiento para la prevencion de la degradacion de la proteina c. - Google Patents

Procedimiento para la prevencion de la degradacion de la proteina c.

Info

Publication number
ES2156190T3
ES2156190T3 ES95300042T ES95300042T ES2156190T3 ES 2156190 T3 ES2156190 T3 ES 2156190T3 ES 95300042 T ES95300042 T ES 95300042T ES 95300042 T ES95300042 T ES 95300042T ES 2156190 T3 ES2156190 T3 ES 2156190T3
Authority
ES
Spain
Prior art keywords
protein
activated
degradation
prevention
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95300042T
Other languages
English (en)
Inventor
Jr Walter Francis Prouty
Josephine Secnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22650141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2156190(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2156190T3 publication Critical patent/ES2156190T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A METODOS PARA PREVENIR O MINIMIZAR LA AUTODEGRADACION DE LA PROTEINA C ACTIVADA. LA INVENCION SE EJEMPLIZA MEJOR A TRAVES DE LA PUESTA EN PRACTICA DEL PROCESAMIENTO, PURIFICACION Y/O ALMACENAMIENTO DE LA PROTEINA C ACTIVADA A PH BAJO, POR EJEMPLO ALREDEDOR DE PH 6,3 A PH 6,5. LA AUTODEGRADACION DE LA PROTEINA C TAMBIEN PODRIA MINIMIZARSE A TRAVES DE LA INCUBACION DE LA PROTEINA C ACTIVADA EN UREA 3 M (RECUPERACION COMPLETA DE LA ACTIVIDAD DE LA PROTEINA C ACTIVADA SE OBTIENE DESPUES DE LA ELIMINACION DEL DESNATURALIZANTE O A TRAVES DE LA INCUVACION DE LA PROTEINA C ACTIVADA EN PRESENCIA DE CONCENTRACIONES DE SAL EXTREMAS). LA PRESENTE INVENCION TAMBIEN CONSTA DE FORMULACIONES APC QUE MANTIENEN LA PROTEINA C ACTIVADA A PH BAJOS, EN DESNATURALIZANTE, O EN CONCENTRACIONES DE SAL EXTREMAS.
ES95300042T 1994-01-05 1995-01-04 Procedimiento para la prevencion de la degradacion de la proteina c. Expired - Lifetime ES2156190T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17783294A 1994-01-05 1994-01-05

Publications (1)

Publication Number Publication Date
ES2156190T3 true ES2156190T3 (es) 2001-06-16

Family

ID=22650141

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95300042T Expired - Lifetime ES2156190T3 (es) 1994-01-05 1995-01-04 Procedimiento para la prevencion de la degradacion de la proteina c.

Country Status (29)

Country Link
EP (2) EP0662513B1 (es)
JP (1) JP3778588B2 (es)
KR (1) KR950032287A (es)
CN (1) CN1109891A (es)
AT (1) ATE201045T1 (es)
AU (1) AU1003195A (es)
BR (1) BR9500017A (es)
CA (1) CA2139468C (es)
CO (1) CO4600680A1 (es)
CZ (1) CZ1395A3 (es)
DE (2) DE10299053I2 (es)
DK (1) DK0662513T3 (es)
ES (1) ES2156190T3 (es)
FI (1) FI115635B (es)
GR (1) GR3036277T3 (es)
HU (1) HUT70465A (es)
IL (1) IL112236A (es)
LU (2) LU90992I2 (es)
NL (1) NL300108I2 (es)
NO (2) NO320157B1 (es)
NZ (1) NZ270271A (es)
PE (1) PE43995A1 (es)
PL (1) PL180703B1 (es)
PT (1) PT662513E (es)
RU (1) RU2167936C2 (es)
SI (1) SI0662513T1 (es)
UA (1) UA39178C2 (es)
YU (1) YU295A (es)
ZA (1) ZA9514B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298429B6 (cs) * 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
EP1557463A1 (en) * 1997-04-28 2005-07-27 Eli Lilly & Company Improved methods for processing activated protein C
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2004511428A (ja) 2000-05-24 2004-04-15 イーライ・リリー・アンド・カンパニー 凝固亢進状態を処置するための製剤および方法
CN101506222B (zh) * 2006-07-14 2013-10-02 健泰科生物技术公司 重组蛋白的重折叠

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950513A (en) * 1965-12-03 1976-04-13 Novo Terapeutisk Laboratorium A/S Process of stabilizing therapeutically useful plasmin solutions
US3557002A (en) * 1967-11-15 1971-01-19 Procter & Gamble Stabilized aqueous enzyme preparation
GB2105521A (en) * 1981-08-12 1983-03-23 Univ Surrey Antenna
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c

Also Published As

Publication number Publication date
NO950018L (no) 1995-07-06
CA2139468C (en) 2007-08-21
EP0662513B1 (en) 2001-05-09
RU95100178A (ru) 1997-03-27
DE10299053I2 (de) 2004-04-01
CA2139468A1 (en) 1995-07-06
DK0662513T3 (da) 2001-05-28
NO320157B1 (no) 2005-11-07
LU90992I2 (fr) 2003-02-18
BR9500017A (pt) 1995-10-03
EP0662513A1 (en) 1995-07-12
RU2167936C2 (ru) 2001-05-27
KR950032287A (ko) 1995-12-20
HU9500021D0 (en) 1995-03-28
JP3778588B2 (ja) 2006-05-24
CN1109891A (zh) 1995-10-11
IL112236A (en) 1999-12-31
NL300108I1 (nl) 2003-02-03
YU295A (sh) 1997-09-30
EP1087011A2 (en) 2001-03-28
NO950018D0 (no) 1995-01-03
FI950044L (fi) 1995-07-06
FI950044A0 (fi) 1995-01-04
CZ1395A3 (en) 1995-07-12
PT662513E (pt) 2001-08-30
FI115635B (fi) 2005-06-15
JPH07206704A (ja) 1995-08-08
NZ270271A (en) 1996-07-26
DE69520844T2 (de) 2001-11-08
ATE201045T1 (de) 2001-05-15
PL306671A1 (en) 1995-07-10
EP1087011A3 (en) 2002-02-06
UA39178C2 (uk) 2001-06-15
SI0662513T1 (en) 2001-10-31
PL180703B1 (pl) 2001-03-30
ZA9514B (en) 1996-07-03
LU90993I2 (fr) 2003-02-18
IL112236A0 (en) 1995-03-30
NL300108I2 (nl) 2003-06-02
DE69520844D1 (de) 2001-06-13
AU1003195A (en) 1995-07-13
GR3036277T3 (en) 2001-10-31
HUT70465A (en) 1995-10-30
PE43995A1 (es) 1995-12-15
CO4600680A1 (es) 1998-05-08
NO2006006I1 (no) 2006-05-15
DE10299053I1 (de) 2003-05-22

Similar Documents

Publication Publication Date Title
PE84799A1 (es) Metodos mejorados para el procesamiento de proteina c activada
KR930702953A (ko) 인체 체모의 제거 또는 성장 억제 약품
NO982721L (no) Preserverende oppl°sning
ES2156190T3 (es) Procedimiento para la prevencion de la degradacion de la proteina c.
DE60023122D1 (de) Verfahren zur verhinderung von hypocalcämie in gebärenden tieren und dazu geeignete zusammensetzungen
BR9005763A (pt) Utilizacao de aminoacidos protegidos contra o ph do rumen na alimentacao do carneiro
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
ATE263574T1 (de) Verwendung von canp-inhibitoren in pharmazeutischen zubereitungen
GR77250B (es)
TR199701227T1 (xx) Pestisidler.
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
ATE132003T1 (de) Sterilisierende zusammensetzung
TH19245A (th) วิธีป้องกันการสลายของโปรตีนซี
IT8464501A0 (it) Procedimento ed impianto per il trattamento di carniccio di conceria per recuperare le frazioni riutilizzabili come grasso, proteine, sali inorganici, acque alcalino solfuree per riduzione scleroproteine.
FI884041L (fi) Desinfiointikoostumus stafylokokkien tappamiseksi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 662513

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: DROTRECOGIN ALFA ACTIVADO (XIGRIS)

Spc suppl protection certif: C200200033

Filing date: 20021203

SPCG Supplementary protection certificate granted

Free format text: DROTRECOGIN ALFA ACTIVADO (XIGRIS)

Spc suppl protection certif: C200200033

Filing date: 20021203

Expiry date: 20170822

Effective date: 20040121